Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 2
1993 3
1994 2
1995 4
1996 4
1997 5
1998 3
1999 2
2000 5
2001 2
2002 6
2003 3
2004 6
2005 1
2006 4
2007 1
2008 3
2009 5
2010 4
2013 2
2014 1
2015 1
2018 1
2019 1
2020 2
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Central and peripheral α-synuclein in Parkinson disease detected by seed amplification assay.
Chahine LM, Beach TG, Adler CH, Hepker M, Kanthasamy A, Appel S, Pritzkow S, Pinho M, Mosovsky S, Serrano GE, Coffey C, Brumm MC, Oliveira LMA, Eberling J, Mollenhauer B; Systemic Synuclein Sampling Study. Chahine LM, et al. Among authors: eberling j. Ann Clin Transl Neurol. 2023 May;10(5):696-705. doi: 10.1002/acn3.51753. Epub 2023 Mar 27. Ann Clin Transl Neurol. 2023. PMID: 36972727 Free PMC article.
Transdermal Nicotine Treatment and Progression of Early Parkinson's Disease.
Oertel WH, Müller HH, Unger MM, Schade-Brittinger C, Balthasar K, Articus K, Brinkman M, Venuto CS, Tracik F, Eberling J, Eggert KM, Kamp C, Kieburtz K, Boyd JT. Oertel WH, et al. Among authors: eberling j. NEJM Evid. 2023 Sep;2(9):EVIDoa2200311. doi: 10.1056/EVIDoa2200311. Epub 2023 Aug 22. NEJM Evid. 2023. PMID: 38320207 Clinical Trial.
GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop.
Barker RA, Björklund A, Gash DM, Whone A, Van Laar A, Kordower JH, Bankiewicz K, Kieburtz K, Saarma M, Booms S, Huttunen HJ, Kells AP, Fiandaca MS, Stoessl AJ, Eidelberg D, Federoff H, Voutilainen MH, Dexter DT, Eberling J, Brundin P, Isaacs L, Mursaleen L, Bresolin E, Carroll C, Coles A, Fiske B, Matthews H, Lungu C, Wyse RK, Stott S, Lang AE. Barker RA, et al. Among authors: eberling j. J Parkinsons Dis. 2020;10(3):875-891. doi: 10.3233/JPD-202004. J Parkinsons Dis. 2020. PMID: 32508331 Free PMC article. Review.
Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial.
Fernandez HH, Weintraub D, Macklin E, Litvan I, Schwarzschild MA, Eberling J, Videnovic A, Kenney CJ; Parkinson Study Group SYNAPSE Investigators. Fernandez HH, et al. Among authors: eberling j. Parkinsonism Relat Disord. 2023 Sep;114:105511. doi: 10.1016/j.parkreldis.2023.105511. Epub 2023 Jul 13. Parkinsonism Relat Disord. 2023. PMID: 37532622 Clinical Trial.
Clinical studies of cerebral blood flow in Alzheimer's disease.
Jagust WJ, Eberling JL, Reed BR, Mathis CA, Budinger TF. Jagust WJ, et al. Among authors: eberling jl. Ann N Y Acad Sci. 1997 Sep 26;826:254-62. doi: 10.1111/j.1749-6632.1997.tb48477.x. Ann N Y Acad Sci. 1997. PMID: 9329697 Review.
Antemortem detection of Parkinson's disease pathology in peripheral biopsies using artificial intelligence.
Signaevsky M, Marami B, Prastawa M, Tabish N, Iida MA, Zhang XF, Sawyer M, Duran I, Koenigsberg DG, Bryce CH, Chahine LM, Mollenhauer B, Mosovsky S, Riley L, Dave KD, Eberling J, Coffey CS, Adler CH, Serrano GE, White CL 3rd, Koll J, Fernandez G, Zeineh J, Cordon-Cardo C, Beach TG, Crary JF. Signaevsky M, et al. Among authors: eberling j. Acta Neuropathol Commun. 2022 Feb 14;10(1):21. doi: 10.1186/s40478-022-01318-7. Acta Neuropathol Commun. 2022. PMID: 35164870 Free PMC article.
76 results